BPC March 30 update

​BioNTech BNTX shares rally on earnings +9%; Seelos SEEL analyst coverage +16%

Price and Volume Movers

BioNTech SE (NASDAQ:BNTX) shares closed up 9% to $104.44 following its release of financial results for the last quarter. In its report it noted that more than 200 million doses of its COVID-19 vaccine, BNT162b2, have been supplied as of March 23, 2021, with signed orders for 1.4 billion doses to date for delivery in 2021, equating to revenues of 9.8 billion. The company recorded COVID-19 vaccine revenues of €270.5 million for the 2020.

Seelos Therapeutics, Inc. (NASDAQ:SEEL) shares closed up 16% to $4.96. Analysts at B.Riley initiated coverage of the stock with a Buy rating and a price target of $15.00.

Moleculin Biotech, Inc. (NASDAQ:MBRX) shares closed up 15% to $4.25 with investors reacting to news that the FDA issued Fast Track Designation (FTD) for its drug, Annamycin, for the treatment of soft tissue sarcoma (STS) lung metastases. FTD is designed to expedite development of pharmaceutical products which demonstrate the potential to address unmet medical needs in serious or life-threatening conditions.

Vaxcyte, Inc. (NASDAQ:PCVX) shares closed down 18% to $18.66 following an update in its earnings report after hours on Monday that its Investigational New Drug (IND) application for VAX-24, its 24-valent pneumococcal conjugate vaccine (PCV), has been delayed to the first half of 2022.

ProQR Therapeutics N.V. (NASDAQ:PRQR) announced after hours that it intends to sell its ordinary shares in an underwritten public offering. Shares are trading down 3% after hours to $6.90 after closing normal hours down 9%.

9 Meters Biopharma, Inc. (NASDAQ:NMTR) also announced that it has commenced a proposed underwritten public offering of shares of its common stock. Shares are trading down 12% to $1.20 after hours.


Major price movers (stocks priced > $1.00, volume > 50k listed on NASDAQ/NYSE):

Refer to the BioPharmCatalyst Biotech Stocks page for Top 10 Gainers/Losers/Unusual Volume:


Savara Inc. (SVRA): $1.94; +22%.

Cyclo Therapeutics, Inc. (CYTH): $8.37; +18%.

Novan, Inc. (NOVN): $1.60; +17%.

Monopar Therapeutics Inc. (MNPR): $6.70; +16%.

AbCellera Biologics Inc. (ABCL): $26.68; +15%.


Wave Life Sciences Ltd. (WVE): $5.96; -16%.

Applied Molecular Transport Inc. (AMTI): $42.01; -14%.

Edgewise Therapeutics, Inc. (EWTX): $31.22; -13%.

Design Therapeutics, Inc. (DSGN): $29.52; -13%.

Osmotica Pharmaceuticals plc (OSMT): $3.51; -12%.

Pipeline updates below:

Pipeline Database Updates

Drug Stage Catalyst Market Cap

ABBV – AbbVie Inc.
Chronic migraine

PDUFA NDA acceptance announced March 30, 2021. PDUFA date late-3Q 2021.
$189.8 billion

AKBA – Akebia Therapeutics Inc.
Anemia due to chronic kidney disease (CKD) in patients on dialysis and not on dialysis.

NDA Filing NDA filing announced March 30, 2021.
$469.7 million

ANGN – Angion Biomedica Corp.
Acute lung injury in patients with COVID-19

Phase 2 Phase 2 data due 1H 2021.
$456.4 million

BCDA – BioCardia Inc.
CardiAMP (BCDA-02)
Chronic Myocardial Ischemia

Phase 3 Phase 3 DSMB review 2Q 2021.
$72.9 million

BLCM – Bellicum Pharmaceuticals Inc.
HER2+ Solid Tumors

Phase 1/2 Phase 1 initial data due 2H 2021.
$29.9 million

CFRX – ContraFect Corporation
CF-301 exebacase (DISRUPT)
Serious infections caused by Staph aureus including MRSA

Phase 3 Phase 3 interim futility analysis due 2H 2021.
$164.8 million

CRBP – Corbus Pharmaceuticals Holdings Inc.
Lenabasum (resunab) - DETERMINE

Phase 3 Phase 3 data due 2Q 2021.
$230.1 million

CRNX – Crinetics Pharmaceuticals Inc.

Phase 3 Phase 3 trials to be initiated 1H 2021 and 2H 2021.
$563.8 million

CWBR – CohBar Inc.
Nonalcoholic Fatty Liver Disease / Obesity / Nonalcoholic steatohepatitis

Phase 1b Phase 1b top-line data due end of 2Q 2021.
$84.7 million

IGMS – IGM Biosciences Inc.
Solid Cancers and Non-Hodgkin’s Lymphoma

Phase 1 Phase 1 initial data due in 2021.
$2.2 billion

KDNY – Chinook Therapeutics Inc.
IgA nephropathy

Phase 1 Phase 1 data to be presented at ISN World Congress of Nephrology meeting from April 15 - 19, 2021. Part 3 data to be reported at the ERA-EDTA Congress from June 5 – 8, 2021..
$624.8 million

KRYS – Krystal Biotech Inc.
B-VEC (Beremagene Geperpavec)
Epidermolysis Bullosa

Phase 3 Phase 3 top-line data due 4Q 2021.
$1.5 billion

PHAT – Phathom Pharmaceuticals Inc.
Vonoprazan PHALCON-HP
H. pylori

Phase 3 Phase 3 top-line data due 2Q 2021.
$1.1 billion

TERN – Terns Pharmaceuticals Inc.
Nonalcoholic steatohepatitis (NASH)

Phase 1b Phase 1b trial to be initiated 1H 2021 with data due 1H 2022.
$475.6 million